Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer.
Multiparameter analysis of core regulatory proteins involved in G1-S and G2-M cell-cycle transitions provides a powerful biomarker readout for assessment of the cell-cycle state. We have applied this algorithm to breast cancer to investigate how the cell cycle impacts on disease progression. Protein expression profiles of key constituents of the DNA replication licensing pathway (Mcm2, geminin) and mitotic machinery (Plk1, Aurora A and the Aurora substrate histone H3S10ph) were generated for a cohort of 182 patients and linked to clinicopathological parameters. Arrested differentiation and genomic instability were associated with an increased engagement of cells into the cell division cycle (P<0.0001). Three unique cell-cycle phenotypes were identified: (1) well-differentiated tumours composed predominantly of Mcm2-negative cells, indicative of an out-of-cycle state (18% of cases); (2) high Mcm2-expressing tumours but with low geminin, Aurora A, Plk1 and H3S10ph levels (S-G2-M progression markers), indicative of a G1-delayed/arrested state (24% cases); and (3) high Mcm2-expressing tumours and also expressing high levels of the S-G2-M progression markers, indicative of accelerated cell-cycle progression (58% of cases). The active cell-cycle progression phenotype had a higher risk of relapse when compared with out-of-cycle and G1-delayed/arrested phenotypes (HR=3.90 (1.81-8.40, P<0.001)), and was associated with Her-2 and triple negative subtypes (P<0.001). It is of note that high-grade tumours with the G1-delayed/arrested phenotype showed an identical low risk of relapse compared with well-differentiated out-of-cycle tumours (HR=1.00 (0.22-4.46), P=0.99). Our biomarker algorithm provides novel insights into the cell-cycle state of dynamic tumour cell populations in vivo. This information is of major prognostic significance and may impact on individualised therapeutic decisions. Patients with an accelerated phenotype are more likely to derive benefit from S- and M-phase-directed chemotherapeutic agents.
Loddo
M
M
Department of Pathology and Cancer Institute, The Paul O'Gorman Building, University College London, Gower Street, London WC1E 6BT, UK.
Kingsbury
S R
SR
Rashid
M
M
Proctor
I
I
Holt
C
C
Young
J
J
El-Sheikh
S
S
Falzon
M
M
Eward
K L
KL
Prevost
T
T
Sainsbury
R
R
Stoeber
K
K
Williams
G H
GH
D064127:Aurora Kinases; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D002453:Cell Cycle; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D042822:Genomic Instability; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D010641:Phenotype; D011003:Ploidies; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000032:analysis
D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases